
Sign up to save your podcasts
Or


The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
By BMJ Group4.8
44 ratings
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).

890 Listeners

221 Listeners

36 Listeners

48 Listeners

7 Listeners

6 Listeners

3 Listeners

1 Listeners

3 Listeners

10 Listeners

40 Listeners

14 Listeners

1 Listeners

50 Listeners

0 Listeners

6 Listeners

16 Listeners

85 Listeners

71 Listeners

236 Listeners

18 Listeners

3 Listeners

19 Listeners

23 Listeners

52 Listeners

11 Listeners

8 Listeners

23 Listeners

4 Listeners

2,073 Listeners

6 Listeners

0 Listeners